T he bacterium Staphylococcus aureus bacteraemia (SAB) is a significant global health problem 1 and is exacerbated by the emergence and widespread circulation of drug-resistant strains such as methicillin-resistant S. aureus (MRSA) 2 . Mandatory surveillance of SAB has been implemented in several countries, with many reporting a decline in the incidence of methicillin-resistant SAB [3] [4] [5] . However, in the UK, the incidence of methicillin-susceptible SAB has been increasing year on year, with an overall increase of more than 15% since reporting became mandatory in 2011/2012 (ref. 3 ). Furthermore, the 30-day (all-cause) mortality rate for SAB has not significantly changed over the last two decades and appears to have plateaued at approximately 20% (ref. 6 ). This strongly suggests that existing infection control and treatment options are insufficient to tackle this important health problem and that a better understanding of the factors that contribute to bacteraemia-associated morbidity is crucially needed.
T he bacterium Staphylococcus aureus bacteraemia (SAB) is a significant global health problem 1 and is exacerbated by the emergence and widespread circulation of drug-resistant strains such as methicillin-resistant S. aureus (MRSA) 2 . Mandatory surveillance of SAB has been implemented in several countries, with many reporting a decline in the incidence of methicillin-resistant SAB [3] [4] [5] . However, in the UK, the incidence of methicillin-susceptible SAB has been increasing year on year, with an overall increase of more than 15% since reporting became mandatory in 2011/2012 (ref. 3 ). Furthermore, the 30-day (all-cause) mortality rate for SAB has not significantly changed over the last two decades and appears to have plateaued at approximately 20% (ref. 6 ). This strongly suggests that existing infection control and treatment options are insufficient to tackle this important health problem and that a better understanding of the factors that contribute to bacteraemia-associated morbidity is crucially needed.
To date, many host risk factors have been identified for both the occurrence of and treatment failure following SAB 6 . However, the contribution of the bacterium is only partially understood and is largely informed by experimental animal studies. These model systems come with their own set of limitations, and many observations contrast with those from human studies. For example, whereas cytolytic toxins have previously been shown to enhance disease severity in animal models of SAB 7, 8 , isolates from invasive diseases in humans, such as bacteraemia and pneumonia, were recently found to be significantly less toxic than those isolated from skin and soft tissue infections or even those of healthy volunteers [9] [10] [11] [12] . This raises the question as to whether animal models are adequate to study bacterial virulence in human SAB infections, or whether there is an important distinction between the role of toxicity in the development of bacteraemia and its pathogenic effect once bacteraemia has been established. Either way, human-based approaches are essential to close this gap in our knowledge.
Our understanding of the pathogenesis of SAB has been further limited by the fact that most studies so far have focused on only a single or small number of factors in isolation. For example, several studies have found increased mortality rates associated with methicillin-resistant SAB compared to methicillin-susceptible SAB 13, 14 . However, patients with comorbidities are more likely to develop methicillin-resistant bacteraemia due to their impaired health and longer time spent in healthcare facilities compared to those without comorbidities. When subsequent studies considered both methicillin resistance and the presence of comorbidities together, no difference in mortality was associated with the methicillin resistance status of the infecting bacterium 15 . This clearly illustrates that multiple host and bacterial factors, as well as their possible interactions, have to be taken into consideration when investigating the outcome of an individual infection.
Clonal differences in Staphylococcus aureus bacteraemia-associated mortality
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We have previously demonstrated how genotype-phenotype mapping in S. aureus has the potential to provide sufficient information to enable predictions of the level of virulence expressed by the infecting microorganism 16 . Here, we have expanded this wholegenome approach to a set of clinical isolates from S. aureus bacteraemic patients, representing two different clonal backgrounds (CC22 and CC30), and determined a number of genetic loci that affect the bacteria's cytolytic toxicity and biofilm formation, both of which are important virulence factors. Using a predictive modelling framework on pooled data comprising genetic, phenotypic and clinical factors, we identified stark differences in the bacterial and host factors most associated with patient death. Our results imply that the clonal background of the infecting microorganism has a more important role in determining the outcome of an infection than previously recognized.
Results
Virulence-specific traits show significant intra-and inter-clonal variation. To elucidate the role of bacterial factors in human SAB we studied a collection of 300 S. aureus isolates belonging to either the multi-locus defined clonal complex 22 or 30 (CC22, n = 135; CC30, n = 165) and containing both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) isolates. Each isolate was quantitatively phenotyped with respect to cytolytic activity (the ability to lyse a monocyte cell line, THP-1) and biofilm formation. Both traits are major virulence determinants implicated in S. aureus disease 1,2 . Cytolytic toxins enable the evasion of cellular aspects of host immunity, release nutrients from host cells, and are responsible for much of the purulent tissue damage associated with S. aureus infections 1,2 , while biofilm formation enables the bacteria to colonize foreign material and medical devices, protects it from many aspects of host immunity, and renders some antibiotics less effective 1, 2 . Despite the close genetic and geographic relationship between the isolates, there was considerable variability with regards to cytolytic toxicity and biofilm formation within the two clonal backgrounds (Fig. 1) . We mapped the level of toxicity and biofilm onto maximum likelihood trees for both collections; this revealed no obvious clustering with respect to genetic relationship and virulence traits ( Supplementary Figs. 1 and 2 ). The distribution in biofilm formation, here normalized relative to a single control strain, was mostly comparable between the two clones, and no apparent difference between MRSA and MSSA strains was observed (Fig. 1c,d) .
Toxicity, on the other hand, was found to be significantly higher in CC22 isolates. We therefore had to dilute the CC22 supernatants to 30% in fresh tryptic soy broth (TSB) to see the variability within this clone, whereas the toxicity assay for CC30 isolates was performed with undiluted supernatant. Although toxicity could not be compared directly between the two clones, it is clear that the distribution in this virulence-associated trait is much more bimodal for bacteria of the CC22 background, with strains showing either very high or very low levels of cytolytic toxicity (Fig. 1a) , which contrasts with the more uniform distribution in the toxicity of CC30 isolates (Fig. 1b) . As with biofilm, no association was found between methicillin susceptibility and this particular virulence phenotype in the CC22 isolates. It has previously been reported that methicillin resistance conferred by the type II SCCmec element in the CC30 clonal background significantly alters the ability of the bacteria to secrete toxins and form biofilm 17, 18 . Here, we could only confirm its effect on toxicity, with MSSA isolates showing significantly elevated levels of cytolytic activity (means of 42% for MRSA and 74% for MSSA, P < 1 × 10 −8
, Welch's two sample t-test).
Genome-wide association scan identifies bacterial virulenceaffecting loci. As the genome sequence for each isolate in these two collections was available, we sought to examine whether the phenotypic and genotypic data presented here would contain sufficient information to enable us to identify the toxicity-and biofilm-affecting loci. We performed a genome-wide association study (GWAS) on both the CC22 and CC30 collections, and associations were tested at an uncorrected (P < 0.05) and a Bonferroni corrected (P < 4.6 × 10 ) significance threshold (Fig. 2a,b) . For biofilm formation, no loci reached significance levels above the Bonferroni threshold for the CC30, whereas 20 loci reached this threshold within the CC22 collection (Fig. 2a,b ). Of these, we were able to functionally verify the effect of five loci using transposon mutants from the Nebraska library 19 ( Fig. 2c and Table 1 ). For toxicity, no loci reached significance levels above the Bonferroni threshold for the CC22 collection, but 95 loci reached it for the CC30 collection. However, of these, we were only able to verify the effects of five ( Fig. 2d and Table 1 ).
Mortality-associated determinants crucially depend on clonal background. For 160 of the 300 bacteraemic patients we had access to their 30-day mortality data, as well as access to some of the established host risk factors for mortality including age, comorbidity index and whether the bacteraemia developed in the community or a healthcare setting (Supplementary Table 1 ). With these Note that the supernatant of the CC22 isolates was diluted to 30%, and the supernatant of the CC30 isolates was used undiluted. Apart from differences in baseline toxicity between the two clones, there is a marked difference in their distribution; for CC22 isolates the toxicity was either very high or very low, but there was a more uniform distribution for CC30. No difference was observed between methicillinresistant (MRSA, grey circles) and methicillin-susceptible (MSSA, black circles) isolates. c,d, Biofilm-forming abilities were quantified relative to a control included in each assay in a static 96-well format. A wide range of biofilm-forming abilities was evident, with no discernible difference between MRSA (grey circles) and MSSA (black circles) isolates.
Isolates of the CC22 (a, n = 136) and CC30 (c, n = 164) backgrounds had comparable distributions.
NaTure MICrOBIOlOgy data and our bacterial genotypic and phenotypic data, we sought to determine which factors were predictive of infection outcome in those 160 patients. Due to the high dimensionality and high number of possible interactions between the various host and bacterial factors, we used a random forests machine learning approach 20, 21 . We analysed the data both in a stratified and in a combined way; that is, we fitted models to each of the phenotype, genotype and clinical/patient data separately, before fitting a model to the pooled data.
Overall, we found that good predictive accuracy could be achieved by fitting a model to the various subsets of data for both the CC22 and CC30 isolates, as shown by receiver operator characteristic (ROC) curves (Fig. 3a,b) . However, the particular features, or predictors, that the models revealed as most important for distinguishing cases where patients died or survived for at least 30 days were crucially dependent on the clonal background of the infecting strain.
For the CC22 collection we found that the bacterial phenotype was more predictive than the host risk factors for which we had , ***P < 2 × 10 −6 ). Results are based on four biological replicates per strain, repeated three times each. Medians are presented as horizontal bars, and boxes and whiskers show the first and third quartile and interquartile ranges. NaTure MICrOBIOlOgy data (AUC = 0.75 compared to AUC = 0.66), whereas the model including all available data showed the best performance, with misclassification rates as low as 22% (Fig. 3c ). Looking at the variable importance scores (Fig. 3e ), a measure of the contribution of the individual features to model performance, confirmed that both virulence factors (toxicity and biofilm) of the infecting bacteria together with the patient's comorbidities are the principal predictors of poor infection outcome. Interestingly, although patient age was selected as one of the more important variables by our feature selection procedure, its power to differentiate between outcomes of infection by strains of this clonal lineage was significantly less than that of the bacteria's phenotype. Supplementary Fig. 3 shows how the interactions between toxicity, biofilm, comorbidity and patient age determine the risk of SAB-associated mortality for this clone, clearly highlighting how the combination of high toxicity or low biofilm with patient age and comorbidities significantly increase the risk of poor infection outcomes in this collection of isolates.
For our CC30 collection we also found good predictive accuracy, but in this case the factors contributing to model performance were very different. In this case, neither the bacterial phenotype nor the data relating to common host risk factors were sufficient to predict 30-day mortality (Fig. 3b) . The model performance significantly improved by considering the bacteria genotype, either by itself or in combination with the other data, and resulted in relatively few misclassification errors, although specificity with respect to patient death was not as high as achieved for the CC22 collection (64% vs 74%). The lack of importance of the phenotype and clinical data in predicting the outcome of CC30-associated bacteraemia is further highlighted in the variable importance plot in Fig. 3f , with the majority of features being related to the bacterial genotype.
It is interesting to note that when the methicillin resistance status of the bacteria was considered in isolation, it was significantly associated with mortality (26% death among MRSA-infected patients vs 14% death among MSSA-infected patients for the CC22 collection and 22% vs 15% for the CC30 collection). However, the model did not identify it as predictive when considered alongside host features such as comorbidity. What this suggests is that patients with higher comorbidity scores are more likely to be infected by MRSA, but their mortality is affected more by their underlying health than the methicillin resistance status of the infecting bacteria, demonstrating the importance of adopting a multivariant approach. More important, however, is that it is very clear from this work that the clonal background of the infecting bacterium has a much greater influence on the severity of infection, and bacteraemia-associated mortality in particular, than previously appreciated.
Functional verification of mortality-associated locus.
Although the feature selection procedure we used should reduce the falsediscovery rate, false positive findings cannot be ruled out without an independent validation data set. We therefore sought to functionally verify true virulence-affecting polymorphisms. Of the 16 loci selected by the model to be predictive of mortality within both the CC22 and CC30 collections, only one encoded a known virulence factors for S. aureus, CapA. The capA gene encodes an enzyme involved in capsule biosynthesis, which is responsible for protecting the bacteria from many aspect of host immunity, and has been shown in animal models to significantly affect disease severity following bacteraemia 22, 23 . Given its role in protecting the bacteria during infection, we hypothesized that variability in capA may affect capsule production and, as a consequence, affect infection outcome.
Within the CC22 collection there were one synonymous and six non-synonymous single nucleotide polymorphisms (SNPs) in this gene. Of these, only one SNP (at position 142543) was distributed disproportionately between isolates from patients who died and those who survived, thus providing the mortality-related signal detected by the model. SNP142543 effects the substitution of a proline at position 146 in the protein with a serine. That all six incidences occurred in isolates from patients who survived their bacteraemia suggests that this substitution may alter capsule quantity or quality to lessen its protective effect. To test this we performed dot-blots on whole bacterial cells using antisera raised against capsule (see Methods). Alongside the appropriate controls we examined the capsule production of 12 isolates from patients who died, all of which had the proline at position 146, and in 12 isolates from patients who survived, half of which had the serine substitution. As demonstrated in Fig. 4a,b , isolates expressing CapA with a serine at position 146 showed a lack of reactivity to the antisera, suggesting that these isolates either produce less capsule or the capsule is sufficiently different in structure to evade antibody recognition.
As the capsule is known to protect S. aureus from killing by phagocytes, we also performed opsinophagocytosis killing (OPK) assays on these 24 clinical isolates, and demonstrated that the isolates with a serine at position 146 of CapA were killed more effectively than those with a proline at this site. A definitive demonstration of the effect of this substitution would require the construction of isogenic mutants, but our aim here was to verify the findings of the predictive model. The fact that capsule production and survival upon exposure to phagocytes, established features that protect the bacteria during infection, are affected in all of the strains with this substitution and none of the 18 without it provides functional support for the sensitivity of the predictive model. 
Discussion
In this study we have demonstrated how S. aureus bacteraemiaassociated mortality is crucially influenced by a variety of host-and bacteria-related factors, and our findings suggest that, of the host and bacterial features we had access to, bacterial phenotype and genotype were the most predictive of infection outcome. From the host perspective, age and comorbidities were the only factors that we found to be predictive of mortality in patients infected with bacteria of the CC22 clonal background. For the CC30 strains, on the other hand, patient age or comorbidities only played a marginal role for correctly distinguishing infection outcomes. The lack of a greater effect of comorbidities for these isolates may be explained by a difference in their prevalence in patients, as within our collection we found that patients with CC22-associated bacteraemia had higher Charlson comorbidity index (CCI) scores on average than those with a bacteraemia caused by a CC30 isolate (3.7 and 2.4, respectively; P = 0.005, Welch's two sample t-test). Furthermore, patients infected with CC22 strains were also significantly older on average (43 years vs 32 years, P < 1× 10
, Welch's two sample t-test). It is therefore possible that, among those infected with a CC30 strain, the existence of comorbidities was less discriminating than for those infected with a CC22 isolate.
Of the bacterial factors we examined, we found significant variability in biofilm formation within the CC22 and CC30 clones but not between them. Animal studies on the role of biofilm in virulence have demonstrated that it is specific to certain types of infection. That is, it may contribute positively to infectious processes involving indwelling catheters but negatively to virulence in sepsis models. Our CC22 data support these findings, with low levels of biofilm being associated with mortality, unlike with the CC30 collection, where neither high nor low levels of biofilm were predictive of patient mortality.
Bacterial toxicity was highly predictive of mortality among the CC22 infected patients, whereas for the CC30 infected patients it was not. This may be explained by the relatively low level of toxicity we and others have reported for this clone 17, 24, 25 . We have previously reported that the antibiotic resistance conferring type II SCCmec element affects the ability of MRSA to secrete toxins 17 , and we see this effect again here, where the mean toxicity for the CC30 MRSA was significantly lower than for MSSA. However, even the MSSA belonging to this clone were less toxic than either methicillin-resistant or susceptible isolates from the CC22 collection, which could be a consequence of clonally associated polymorphisms in regulators of toxicity, such as Agr (ref. 24 ). This clone appears, therefore, 
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to be inherently constrained in its ability to produce toxins, and as such must utilize alternative and as yet to be elucidated means of causing damage to the host. Our results from the two clones studied here contrast with those of another study that also looked at toxicity (although they used the term 'agr dysfunction'); they found that low levels of toxicity were associated with increased mortality among the most severely ill patients in their study 26 . The study contained multiple S. aureus clones, and it would be interesting to see if the effect they found was specific to individual clones.
The multivariate approach taken here also provides some clues regarding other bacterial factors linked to the mortality of bacteraemic patients. We functionally verified the effect of one of those: the polymorphism in the capA gene that appears to affect capsule production and consequently the ability of the bacteria to protect itself from host immunity. For the CC30 collection, polymorphisms in the drp35 gene were the most predictive of mortality, and this gene has been shown to be upregulated in response to exposure to specific antibiotics 27 , suggesting that an enhanced ability to survive such pressures may increase the ability of the bacteria to kill their host.
In addition to identifying factors that affect mortality, we have also used our bacterial phenotypic and genotypic data to identify the effectors of toxicity and biofilm by adopting a GWAS approach, and verified their effect using transposon mutants ( Fig. 2 and Table 1 ). Helicases are involved in unwinding DNA for processes such as transcription. Given that the loss of this gene (NE513) results in a decrease in biofilm formation, this suggests that this helicase may be responsible for unwinding genes involved in increasing the amount of biofilm a bacterium produces. The involvement of the quinolone efflux pump NorA (NE1034) is intriguing, given the coincidence of biofilm with increased antibiotic resistance. Inactivation of the peptidase (NE1455) also causes an increase in biofilm formation, and it is thus possible that it may have a direct effect on breaking down the proteinaceous components of biofilm. The role of the other genes in toxicity and biofilm formation is currently unclear, but work to elucidate this is under way.
GWAS in any species is prone to produce spurious associations, and for this data set our approach generated a 70% (14/20) false positive rate for biofilm formation and 95% for toxicity (90/95). It is clear that there is significant variability in the success rate of this approach, and this may be due to the presence of loci with varying effects on the phenotype in question. However, given that these can be readily identified and discounted in bacteria using mutants from transposon libraries, we believe that it is still a suitable approach to identify candidate loci while avoiding the need to screen entire mutant libraries consisting of thousands of individual mutants.
It is likely that other factors not considered here may also contribute to a patient's risk of death following SAB. Apart from patient care, host genotype and other bacterial phenotypes could have a significant effect on infection outcome. A larger, more detailed data set may enable us to fully identify these factors and unravel their interactions to predict mortality with even higher accuracy. However, given the general complexity of this type of disease and its epidemiology, where older patients with comorbidities are the most susceptible, it might never be feasible to fully predict infection outcome.
With the growing global problem of antimicrobial resistance, alternative intervention and control strategies are needed. These include the development of vaccines and the identification of drugs that attenuate the virulence of pathogens. However, without a full understanding of how the bacterial targets for these strategies are involved in causing disease in humans, there is a significant risk of investing in and pursuing unsuccessful lines of therapeutic development. For example, our findings suggest that cytolytic toxins, components of biofilm and capsules are unlikely to be good targets due to their disparate roles in different stages of disease and their highly variable expression between and even within closely related bacterial clones. With the move towards the introduction of microbial genome sequencing into routine diagnostic settings, the ability to use such information to inform clinicians on the likely outcome of an infection for individual patients would allow them to tailor treatment to that individual. Our work therefore has the potential to isolates using antiserum raised against a type 5 S. aureus capsule by dot-blotting (a representative blot is shown). Twelve of the isolates were from patients who survived bacteraemia (alive) and 12 were from patients who did not survive bacteraemia (dead). Of the strains from patients who survived, six contained a proline (P) at position 146 of CapA, and the other six contained a serine (S). b, Dot-blots were performed three times, and the intensity of the reaction of each strain was quantified. Mean intensity for each isolate is presented. Isolates containing the serine were significantly less reactive to the antiserum. c, To compare the protective qualities of the capsule we performed opsinophagocytosis assays using human PMNs with each of the 24 isolates. The percentage of each of the 24 clinical isolates that were killed are presented (performed in triplicate). Welch's two-sided t-test: **P < 2 × 10
, ***P < 2 × 10
). In panels b and c, the medians are presented as horizontal bars, with the boxes and whiskers showing the first and third quartile and interquartile range. NaTure MICrOBIOlOgy make a significant contribution to the implementation of personalized medicine and infectious disease management.
Methods
Strain and clinical metadata collection. All isolates were collected from patients admitted to a single hospital with their first episode of SAB between 2006 and 2012, and were stored in glycerol at − 80 °C. Samples were collected during an observational cohort study of adults with SAB at Addenbrooke's Hospital, Cambridge, UK, between 2006 and 2012. These isolates represented the genetic diversity present across the British Society for Antimicrobial Chemotherapy collection of sequenced CC22 and CC30 isolates collected from multiple sites across the UK and Ireland since 2008. Written informed consent was not required as the study was conducted as part of a service evaluation of the management of SAB. Ethical approval was obtained from the University of Cambridge Human Biology Research Ethics Committee (reference HBREC.2013.05) and the Cambridge University Hospitals NHS Foundation Trust Research and Development Department (reference A092869). Study definitions have been defined previously 28 and were used to determine the focus of the bacteraemia, classify the bacteraemia as community-acquired, hospital-acquired or healthcareassociated, and to report outcomes, including death at 30 days. The previously defined definitions 28 were placed into eight categories; intravascular catheter infection (SAB caused from a central or peripheral venous catheter), bone and joint infection (SAB due to a native joint infection), deep tissue abscess (infection due to lung infection, deep tissue abscesses, mycotic aneurysms and lesions in the central nervous system), infective endocarditis, infection due to a prosthetic device (including prosthetic joints, implanted vascular devices, prosthetic cardiac valves), skin and soft tissue infection, disease of the urogenital tract, or an unknown focus of infection. The presence of comorbidities was assessed using the CCI and dichotomized into scores of < 3 or ≥ 3 (refs 29, 30 ), as detailed in Supplementary Table 1 .
Genome sequencing. Bacterial DNA extraction was carried out on a QIAxtractor (Qiagen), and library preparation was performed as previously described 31 . Index-tagged libraries were created, and 96 separated libraries were sequenced in each of eight channels using the Illumina HiSeq platform (Illumina) to generate 100 bp paired-end reads at the Wellcome Trust Sanger Institute, UK. Paired-end reads for these isolates were mapped to either the ST22/EMRSA15 reference strain, HO 5096 0412 (ref. 32 ) or the CC30/EMRSA16 reference strain MRSA252 (ref.
33
) and SNPs were identified as described previously 32 . The accession numbers for the sequence data for each of these isolates are listed in Supplementary Table 1 .
Cytotoxicity assay. Overnight S. aureus cultures were diluted 1:1,000 into fresh tryptone soya broth and incubated for 18 h at 37 °C with shaking at 180 r.p.m. in 30 ml glass tubes. S. aureus supernatants were collected from 18 h cultures by centrifugation at 14,600 r.p.m. for 10 min. The THP-1 human monocytemacrophage cell line (ATCC#TIB-202, which was authenticated and tested for mycoplasma) was routinely grown in suspension in 30 ml of RPMI-1640, supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1 μ M l-glutamine, 200 units ml −1 penicillin, and 0.1 mg ml −1 streptomycin at 37 °C in a humidified incubator with 5% CO 2 . Cells were routinely viewed microscopically every 48-60 h, collected by centrifugation at 1,000 r.p.m. for 10 min at room temperature, and resuspended to a final density of 1-1.2 × 10 6 cells ml −1 in tissuegrade phosphate buffered saline. This procedure typically yielded > 95% viability of cells, as determined by trypan blue exclusion and easyCyte flow cytometry. To evaluate S. aureus toxicity, for the CC30 isolates undiluted supernatant was used, but due to the higher toxicity of the CC22 isolate the supernatant was diluted to 30% of the original volume in TSB. The neat and diluted bacterial supernatants (20 µ l) were incubated with 20 µ l of washed THP-1 cells for 12 min at 37 °C under static conditions. Cell death was quantified by easyCyte (Millipore) flow cytometry using the Guava Viability stain (Millipore) according to the manufacturer's instructions, with the toxicity of each isolate quantified in triplicate and the mean of this presented (Supplementary Table 1 ).
Biofilm assay. Biofilm formation was quantified using a 1:40 dilution from overnight cultures into 100 µ l of fresh tryptic soy broth supplemented with 0.5% sterile filtered glucose (TSBG) in a 96-well polystyrene plate (Costar). Perimeter wells of the 96-well plate were filled with sterile H 2 O, and plates were placed in a separate plastic container inside a 37 °C incubator and grown for 24 h under static conditions. For the transposon mutants, erythromycin (5 µ g ml ) was added to the growth medium. Semi-quantitative measurements of biofilm formation on the 96-well polystyrene plates was determined based on the method of Ziebuhr and colleagues 34 . Following growth for 24 h, plates were washed vigorously five times in PBS, dried, and stained with 150 μ l of 1% crystal violet for 30 min at room temperature. Following five washes of PBS, wells were resuspended in 200 μ l of 7% acetic acid, and the optical density at 595 nm was recorded using a fluorimeter plate reader (BMG Labtech). To control for day to day variability, for the clinical isolates a control strain (E-MRSA15) was included on each plate in triplicate, and absorbance values were normalized against this (listed in Supplementary Table 1) . For the transposon mutants, because JE2 is the wild-type strain, this was used as the control strain, and the effect of mutating the loci was determined relative to this. Assays were performed in triplicate on each plate and repeated four times.
GWAS.
The genomes of reference strains HO 5096 0412 and MRSA252 were split into loci corresponding to coding regions and intergenic regions, and loci in the clinical isolates containing SNPs relative to their reference genome were identified. Annotated intergenic elements such as miscellaneous RNAs were considered separate loci. Synonymous SNPs in coding regions and SNPs in known mobile genetic elements and repeat regions were not considered. The resulting loci were named allele_X, where X refers to the position of the SNP at the 5′ end of that block, relative to the origin of replication. Each of these alleles in each isolate was scored as 1 if it differed from the reference and 0 if it did not. These allele scores for each isolate were used as the genotypic information for the following analysis. Significant associations between bacterial genotype and either phenotype (toxicity and biofilm formation) were identified by fitting an analysis of variance model (ANOVA) in R (ref. 35 ) and using a minor allele frequency cutoff of 5%. The reported P values were not corrected for multiple testing, and the Bonferroni statistical significance threshold is instead provided in Fig. 3 .
Predictive modelling. We used a Random Forests 20 machine learning approach, using the randomForest package in R (ref. 21 ), to identify the most important and clone-specific determinants for host mortality based on the genotype, phenotype and clinical metadata (see Supplementary file S1_RF_analysis.pdf for full details). The input variables were thus taken from the pooled set of SNP data, relative cytolytic toxicity, relative biofilm formation and infection/patient-specific data for each isolate. Due to the genetic differences between CC22 and CC30, where only a small proportion of SNP positions overlapped, we carried out the analysis for both clones separately.
Predictive accuracy. To assess the model's predictive accuracies we used two different measures: (1) the ROC curve, which is generated by plotting the true positive rate against the false positive rate (that is, the observed incidence against the false predicted incidence) at various threshold settings and where the area under the curve (AUC) is a measure of predictive accuracy, with AUC = 1 equating to zero error and AUC = 0.5 equating to random guessing; and (2) by means of a confusion matrix, which contrasts the instances of the predicted classes (alive or death) against the actually observed classes. The misclassification rates reported here are based on the so-called out-of-bag errors 21 , which are derived by iteratively testing the models' performances against subsets of data left out during the fitting processes and thus provide a measure of how well the models would fare against unknown data.
Feature selection. Due to the high dimensionality of the combined data set including genotype, phenotype and clinical data, where the number of features significantly outweighed the number of clinical samples, we performed a feature selection procedure using the VSURF (ref. 36 ) R package nested within a tenfold cross-validation procedure. The VSURF algorithm selects features based on the stepwise introduction of predictors in order of their importance ranking with regards to their contribution to model performance. At each fold, a small number of features (in our case between 3 and 20) were selected, from which we then took only those that were selected more than once to form our final feature set. This procedure reduces the risk of overfitting and ensures that only those features are considered that are important across a wide range of isolates. See Supplementary Information for a detailed overview of our analysis, including the feature selection procedure and parameter settings 36 .
Capsule dot-blots. Bacteria were grown overnight in TSB at 37 °C with shaking. A 5 μ l volume of overnight culture was spotted onto nitrocellulose membranes, and the membranes were dried for 10 min at 65 °C. The membranes were washed three times in PBS and then once for 1 h at 37 °C in PBS with 2 mg ml −1 trypsin. Membranes were then blocked in 0.05% skim milk for 1 h, and washed three times in PBS with 0.05% Tween (PBS-Tween). Anti-Cap5 antiserum (a gift from J. Lee, Harvard) was diluted 1:1,000 in the PBS-Tween buffer and the membrane was incubated in this with gentle agitation for 1 h at room temperature. The membranes were washed three time in PBS-Tween. The protein A-HRP conjugate was diluted 1:1,000 in PBS-Tween and the membrane was incubated in this with gentle agitation for 1 h at room temperature. The membranes were washed and the reactivity of the antiserum detected using the colorimetric substrate 4-chloro-1-napthol. The blots were scanned and the density of capsule antiserum reactivity quantified using the ImageJ software. Each strain was blotted three times and the average density of the three repeats for each isolate is presented.
Opsinophagocytosis assays. Polymorphonuclear leukocytes (PMNs) from healthy human volunteers were separated from heparinized blood by density centrifugation. The cells were washed and resuspended at a density of 10 7 cells per ml. The opsinophagocytosis killing assays were performed in 5 × 10 6 PMNs, 10% (vol/vol) human serum and 10 6 colony-forming units (c.f.u.) of each of the S. aureus isolates. This was incubated with gentle agitation for 2 h at 37 °C, NaTure MICrOBIOlOgy followed by diluting and plating onto TSA plates to enumerate the live bacteria. The data presented are the % killed bacteria for each of the 24 clinical isolates in triplicate.
Data availability. All of the data collected and analysed in this study are provided in the Supplementary Information.
